lc16m8

LC16m8 is a next-generation, attenuated smallpox vaccine derived from the Lister vaccinia virus strain and produced in cell culture. It is designed to have an improved safety profile compared to traditional smallpox vaccines while maintaining efficacy. The vaccine lacks the B5R protein, which contributes to its attenuation. LC16m8 generates neutralizing antibody titers against multiple poxviruses—including vaccinia, monkeypox (mpox), and variola major—and elicits broad T-cell responses. It is minimally replicating in humans and has been licensed for use in Japan for both smallpox and mpox prevention. Clinical trials have demonstrated robust immunogenicity with fewer adverse effects than older vaccines, making it suitable for targeted vaccination of at-risk groups such as those with well-controlled HIV infection[1][2][3][4][5][6].

Brand names

LC16m8LC-16m8LC 16m8

Other names

LC16m8 smallpox vaccineLC-16m8 smallpox vaccineLC 16m8 smallpox vaccineattenuated vaccinia virus LC16m8cell culture-adapted smallpox vaccine LC16m8LC16KMB smallpox vaccineLC-16KMB smallpox vaccineLC 16KMB smallpox vaccine